Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) (PACIFIC-4/RTOG-3515)

Administered By

Awarded By

Contributors

Start/End

  • January 2, 2020 - March 29, 2022